ArticleJournal of cancer research and clinical oncology2019
DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
Article in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- A systematic evaluation of double-expressor lymphoma: prognostic impact, determinants of outcome, and comparative efficacy and safety of novel therapies.Frontiers in oncology · 2026Pooled it
- DA-EPOCH-R improves the prognosis of patients with double-expressor lymphoma: A single-center retrospective study and meta-analysis.Medicine · 2022Pooled it
- Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort-A Turkish Oncology Group (TOG) Study.Medicina (Kaunas, Lithuania) · 2026Article
- Real-world effectiveness of zanubrutinib plus salvage chemotherapy in relapsed or refractory double-expressor DLBCL.Annals of hematology · 2026Article
- Optimizing first-line therapy for double-expressor lymphoma: a systematic review and meta-analysis of novel agent-augmented R-CHOP regimens.Cancer cell international · 2026Review
- CD5-positive diffuse large B-cell lymphoma of the uterus: a Case Report with cytologic findings from uterine cavity drainage and literature review.Frontiers in oncology · 2026Article
- Cecal Involvement of Diffuse Large B-Cell Lymphoma: A Rare Extra-Nodal Presentation.Journal of medical cases · 2025Article
- Recent advancements in double-expressor lymphoma: novel therapeutic approaches and prospects.The oncologist · 2025Review
- Lymphoma Imaging in HIV and Non-HIV Patients: A Retrospective Cross-Sectional Study With Clinical and Pathological Correlation.Cancer informatics · 2025Article
- Article
- Chidamide represses MYC expression and might improve survival for patients with double expressor lymphoma.American journal of cancer research · 2024Article
- Real-world efficacy of chidamide plus R-CHOP in newly diagnosed double-expressor diffuse large B-cell lymphoma.Therapeutic advances in hematology · 2024Article
- Prognosis and complete remission rate of diffuse large B-cell lymphoma patients in standard R-CHOP with reduction of vincristine: A retrospective study.Health science reports · 2023Article
- Clinical significance of plasma PD-L1Annals of hematology · 2023Article
- [MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Machine Learning Models for the Diagnosis and Prognosis Prediction of High-Grade B-Cell Lymphoma.Frontiers in immunology · 2022Article
- Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data.International journal of hematology · 2020Article
- [Feasibility of PEG-rhG-CSF in the first-line treatment of diffuse large B-cell lymphoma receiving dose-adjusted EPOCH plus rituximab].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.American journal of hematology · 2020Article
- A Case of Double Expresser Diffuse Large B Cell Lymphoma Treated with R-CODOX-M/R-IVAC.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThis study was to compare DA-EPOCH-R and R-CHOP regimen as first-line therapy in diffuse large B cell lymphoma (DLBCL) patients, retrospectively.
methodsA total of 252 cases treated with R-CHOP and 146 cases who received DA-EPOCH-R were enrolled into this study.
resultsOverall, 162 (64.3%) and 105 patients (71.9%) achieved complete remission, 43 (17.1%) and 14 patients (9.6%) achieved partial remission following R-CHOP and DA-EPOCH-R regimen, respectively. After a median follow-up of 48 months, better progression-free survival (PFS) was seen in DA-EPOCH-R group, but no better overall survival (OS) was found in patients treated with DA-EPOCH-R compared to R-CHOP (P = 0.015 for PFS, P = 0.19 for OS). However, subgroup analysis according to cell of origin, international prognostic index (IPI), and age showed DA-EPOCH-R resulted in significantly better PFS and OS than R-CHOP regimen in patients with germinal center B-cell-like (GCB) phenotype (P = 0.002 for PFS, P = 0.007 for OS), high IPI (P = 0.002 for PFS; P = 0.03 for OS), and with a younger age (P = 0.002 for PFS, P = 0.045 for OS). We also compared two regimens in patients with double expressor lymphoma (DEL). The prognosis of DEL patients was significantly worse than non-DEL patients (P < 0.001 for PFS, P < 0.001 for OS), but DA-EPOCH-R regimen may not overcome the poor prognosis (P = 0.47 for PFS, P = 0.79 for OS).
conclusionGCB DLBCL, younger patients, and high-risk patients, but not DEL patients, may benefit from continuous-infusion DA-EPOCH-R regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.